Twist Bioscience Corp vs Vanguard S&P 500 Growth Index Fund ETF — how do they compare? Twist Bioscience Corp trades at $158.85 (market cap $10.08B), while Vanguard S&P 500 Growth Index Fund ETF trades at $87.08 (market cap $27.10B). The key difference: Vanguard S&P 500 Growth Index Fund ETF is far larger — about 2.7× Twist Bioscience Corp's market cap, and Vanguard S&P 500 Growth Index Fund ETF is trading nearer its 52-week high, Twist Bioscience Corp nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Twist Bioscience Corp for 27 Days and Vanguard S&P 500 Growth Index Fund ETF for 54 Days on average.
| TWST | VOOG | |
|---|---|---|
Market Cap | $10.08B | $27.10B |
Volume | 4,229,037 | 1,178,312 |
Sector | Health | Broad Market / Factor |
52-Week High | $205.00 | $87.81 |
52-Week Low | $25.45 | $65.32 |
Typical Hold Time | 27 Days | 54 Days |
Enterprise Value | $10.01B | — |
Signals from Pluang's Aura AI — not financial advice
TWST trades at $155.65, down 6.78% over 24 hours, with a bearish technical signal and negative cash flows. Revenue growth is strong, reaching $377M in 2025, but the company remains unprofitable with a net income margin of -31.66%. Recent news highlights its role in Eli Lilly's AI-driven drug discovery platform, boosting sentiment despite earnings misses.
The outlook is mixed: analyst consensus is bullish with a $145.20 price target, but high valuation multiples and persistent losses pose risks. Investment opportunity hinges on AI partnerships driving future profitability, while execution risks and cash burn require careful monitoring.
VOOG trades at $87.69, down slightly by 0.14% on the day, with technical indicators showing mixed signals—bullish moving averages but bearish oscillators including an overbought RSI. The ETF, tracking the S&P 500 Growth Index, has delivered strong long-term returns, with recent news highlighting institutional buying and outperformance versus peers. Key support sits at $87, resistance at $88.
Outlook remains positive for long-term growth investors given VOOG's low expense ratio and historical outperformance, though near-term risks include tech sector concentration and market volatility. The ETF's focus on large-cap growth stocks positions it well for sustained appreciation, but investors should be cautious of valuation extremes in growth segments.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →VOOG is an index-based ETF that tracks the S&P 500 Growth Index, composed of the growth-oriented companies within the S&P 500. It selects constituents based on three key metrics—sales growth, the ratio of earnings change to price, and momentum—offering a highly liquid and low-cost way to capture the high-performing 'growth slice' of the broader U.S. large-cap market.
Read more on VOOG →